Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02279992 · ClinicalTrials.gov registry record · Early Phase 1

Pilot Study of Vardenafil and Carboplatin in Patients With Gliomas and Brain Metastases

A Early Phase 1 study, sponsored by Cedars-Sinai Medical Center.

Terminated
Registry status
Early Phase 1
Development phase
7
Enrollment target

NCT02279992: Clinical Trial Early Phase 1 study, sponsored by Cedars-Sinai Medical Center.

NCT02279992 is a Early Phase 1 study that was terminated before completion, run by Cedars-Sinai Medical Center. The registered enrollment target is 7 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02279992, a Early Phase 1 study, was terminated before completion, sponsored by Cedars-Sinai Medical Center.

TERMINATED
Registry status
Early Phase 1
Development phase
7 participants
Enrollment target

Study Summary

This is a randomized pilot study to investigate the ability of a phosphodiesterase-V inhibitor (vardenafil) to increase the concentration of systemically delivered chemotherapy, carboplatin, in patients with recurrent malignant gliomas or metastatic brain cancer. This study will also determine the toxicity and tolerability of a phosphodiesterase-V inhibitor (vardenafil) in combination with intravenous carboplatin for patients with recurrent malignant gliomas or metastatic brain cancer.

Interventions

  • DRUG Carboplatin
  • DRUG Vardenafil

Trial Details

FieldValue
Enrollment Target 7 participants
Start Date 2012-03-27
Est. Completion 2016-02-11
Phase Early Phase 1
Cedars-Sinai Medical Center

339 total trials

Why NCT02279992 stopped before completion

NCT02279992 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (87% lower).

The record links to 0 conditions, and to 2 interventions - of which Carboplatin is the first listed.

NCT02279992 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02279992 about?

NCT02279992 is a clinical study titled "Pilot Study of Vardenafil and Carboplatin in Patients With Gliomas and Brain Metastases". This is a randomized pilot study to investigate the ability of a phosphodiesterase-V inhibitor (vardenafil) to increase the concentration of systemically delivered chemotherapy, carboplatin, in patients with recurrent malignant gliomas or metastatic brain cancer. This study will also determine the t...

What is the current status of trial NCT02279992?

This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 7 participants. The study started on 2012-03-27. Estimated completion is 2016-02-11.

What interventions are being tested in trial NCT02279992?

The interventions under investigation include: Carboplatin (DRUG), Vardenafil (DRUG).

Who is sponsoring clinical trial NCT02279992?

This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02279992's enrollment target sits among peer trials

7 1825th of 2000 higher than 156 of 2,000 other Early Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02279992, the US trial registry maintained by the National Library of Medicine. NCT02279992 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.